SCHEMBL2333201

SCHEMBL2333201

COCCN1C(=O)c2ccccc2C(CNc2cccc(OC)c2)C1c1cccs1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.43
MAPK1 P28482 2/20 0.43
HSD17B10 Q99714 1/20 0.43
GAA P10253 3/20 0.41
MAPT P10636 2/20 0.40
KDM4E B2RXH2 2/20 0.40
HTT P42858 1/20 0.40
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
TSHR P16473 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
NPSR1 Q6W5P4 3/20 0.37
PKM P14618 1/20 0.36
FFAR1 O14842 1/20 0.36
MEN1 O00255 1/20 0.36
HPGD P15428 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2333915 0.85 MDM2 (0.41) ALDH1A1HSD17B10GAAMAPTKDM4E
SCHEMBL2379425 0.83 GAA (0.60) ALDH1A1GAAMAPTKDM4EHTT
SCHEMBL2337039 0.83 GAA (0.60) ALDH1A1GAAMAPTKDM4EHTT
SCHEMBL2379561 0.83 GAA (0.60) ALDH1A1GAAMAPTKDM4EHTT
SCHEMBL2334732 0.79 GAA (0.58) ALDH1A1GAAMAPTKDM4EHTT
SCHEMBL2337539 0.79 ALDH1A1 (0.46) ALDH1A1HSD17B10GAAMAPTKDM4E
SCHEMBL2335016 0.77 CYP2C9 (0.54) ALDH1A1GAAMAPTKDM4EHTT
SCHEMBL2330960 0.77 GAA (0.57) ALDH1A1GAAMAPTKDM4EHTT
SCHEMBL2335774 0.77 GAA (0.54) ALDH1A1HSD17B10GAAMAPTKDM4E
SCHEMBL2332851 0.76 ALDH1A1 (0.51) ALDH1A1HSD17B10GAAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224208-A1 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2011-09-15 US claimed
US-20110224208-A1 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2011-09-15 US disclosed
EP-2358682-A2 ISOQUINOLONE DERIVATIVES AS INHIBITORS OF PLAVIVIRUS REPLICATION Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2011-08-24 EP disclosed
WO-2010055164-A2 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224208-A1 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION MAVS, IRF3, EIF2AK2 ALDH1A1 2613/4885MAPK1 2096/4885HSD17B10 1021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.